CN105517546A - 治疗脆性x综合征及相关疾病的方法 - Google Patents
治疗脆性x综合征及相关疾病的方法 Download PDFInfo
- Publication number
- CN105517546A CN105517546A CN201480049671.5A CN201480049671A CN105517546A CN 105517546 A CN105517546 A CN 105517546A CN 201480049671 A CN201480049671 A CN 201480049671A CN 105517546 A CN105517546 A CN 105517546A
- Authority
- CN
- China
- Prior art keywords
- metadoxine
- mice
- hours
- release
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361875384P | 2013-09-09 | 2013-09-09 | |
| US61/875,384 | 2013-09-09 | ||
| US14/038,258 | 2013-09-26 | ||
| US14/038,258 US20150073023A1 (en) | 2013-09-09 | 2013-09-26 | Method Of Treating Fragile X Syndrome And Related Disorders |
| US201461991351P | 2014-05-09 | 2014-05-09 | |
| US61/991,351 | 2014-05-09 | ||
| PCT/IB2014/002398 WO2015033224A2 (en) | 2013-09-09 | 2014-09-09 | Methods of treating fragile x syndrome and related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105517546A true CN105517546A (zh) | 2016-04-20 |
Family
ID=52629036
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480049671.5A Pending CN105517546A (zh) | 2013-09-09 | 2014-09-09 | 治疗脆性x综合征及相关疾病的方法 |
| CN201480060722.4A Pending CN105917225A (zh) | 2013-09-09 | 2014-09-09 | 确定治疗应答的方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480060722.4A Pending CN105917225A (zh) | 2013-09-09 | 2014-09-09 | 确定治疗应答的方法 |
Country Status (12)
| Country | Link |
|---|---|
| EP (2) | EP3044589A1 (enExample) |
| JP (2) | JP2016530536A (enExample) |
| KR (2) | KR20160078956A (enExample) |
| CN (2) | CN105517546A (enExample) |
| AU (2) | AU2014316779A1 (enExample) |
| CA (2) | CA2923421A1 (enExample) |
| EA (2) | EA201690559A1 (enExample) |
| IL (2) | IL244343A0 (enExample) |
| MX (2) | MX2016003002A (enExample) |
| SG (2) | SG11201601605YA (enExample) |
| TW (2) | TW201606304A (enExample) |
| WO (2) | WO2015033224A2 (enExample) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108538365A (zh) * | 2017-03-24 | 2018-09-14 | 华东师范大学 | 一种基于数据分析技术的自闭症社交能力评估系统 |
| CN112055587A (zh) * | 2018-04-13 | 2020-12-08 | Healx有限公司 | 脆性x综合征的治疗 |
| CN112770739A (zh) * | 2018-06-07 | 2021-05-07 | 奥维德医疗公司 | (s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸及相关化合物、(1s,3s)-3-氨基-4-(二氟亚甲基)环戊烷-1-甲酸以及氨己烯酸在治疗发育障碍中的用途 |
| CN115812000A (zh) * | 2020-06-29 | 2023-03-17 | Zyne制药公司 | 大麻二酚对脆性x综合征的治疗 |
| US12582664B2 (en) | 2022-10-20 | 2026-03-24 | Harmony Biosciences Management, Inc. | Treatment of fragile x syndrome with cannabidiol |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3239161A1 (en) * | 2013-07-31 | 2017-11-01 | UDC Ireland Limited | Luminescent diazabenzimidazole carbene metal complexes |
| US20150073023A1 (en) | 2013-09-09 | 2015-03-12 | Alcobra Ltd. | Method Of Treating Fragile X Syndrome And Related Disorders |
| KR20190121569A (ko) * | 2018-04-18 | 2019-10-28 | 건국대학교 글로컬산학협력단 | 아그마틴 및 이의 약학적으로 허용 가능한 염을 포함하는 취약 x 증후군 예방 또는 치료용 약학조성물 |
| WO2021141426A1 (ko) * | 2020-01-08 | 2021-07-15 | 건국대학교 글로컬산학협력단 | 리수리드 화합물을 유효성분으로 포함하는 취약 x 증후군 또는 관련 발달 장애 치료용 조성물 |
| CN119139297A (zh) * | 2020-02-07 | 2024-12-17 | 株式会社纽若梵提 | 包含利美尼定的组合物的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1131856B (it) | 1980-06-30 | 1986-06-25 | Baldacci Lab Spa | Composizione farmaceutica per il trattamento di intossicazioni alcooliche |
| AU2002236527A1 (en) * | 2000-11-30 | 2002-06-11 | The Health Research Institute | Nutrient supplements and methods for treating autism and for preventing the onset of autism |
| IL187159A0 (en) | 2007-07-03 | 2009-02-11 | Gur Megiddo | Use of metadoxine in relief of alcohol intoxication |
| JP5770173B2 (ja) * | 2009-06-25 | 2015-08-26 | アルコブラ、リミテッドＡｌｃｏｂｒａ Ｌｔｄ． | 認知疾患、障害または病態の治療、症状緩和、軽減、改善および予防方法 |
-
2014
- 2014-09-05 TW TW103130859A patent/TW201606304A/zh unknown
- 2014-09-05 TW TW103130856A patent/TW201605443A/zh unknown
- 2014-09-09 MX MX2016003002A patent/MX2016003002A/es unknown
- 2014-09-09 KR KR1020167009040A patent/KR20160078956A/ko not_active Withdrawn
- 2014-09-09 WO PCT/IB2014/002398 patent/WO2015033224A2/en not_active Ceased
- 2014-09-09 KR KR1020167009042A patent/KR20160086818A/ko not_active Withdrawn
- 2014-09-09 JP JP2016540930A patent/JP2016530536A/ja active Pending
- 2014-09-09 MX MX2016003006A patent/MX2016003006A/es unknown
- 2014-09-09 SG SG11201601605YA patent/SG11201601605YA/en unknown
- 2014-09-09 EP EP14776939.2A patent/EP3044589A1/en not_active Withdrawn
- 2014-09-09 CN CN201480049671.5A patent/CN105517546A/zh active Pending
- 2014-09-09 EA EA201690559A patent/EA201690559A1/ru unknown
- 2014-09-09 AU AU2014316779A patent/AU2014316779A1/en not_active Abandoned
- 2014-09-09 JP JP2016539645A patent/JP2016530291A/ja active Pending
- 2014-09-09 CN CN201480060722.4A patent/CN105917225A/zh active Pending
- 2014-09-09 EA EA201690557A patent/EA201690557A1/ru unknown
- 2014-09-09 EP EP14830858.8A patent/EP3043792A2/en not_active Withdrawn
- 2014-09-09 AU AU2014315026A patent/AU2014315026A1/en not_active Abandoned
- 2014-09-09 WO PCT/US2014/054816 patent/WO2015035402A1/en not_active Ceased
- 2014-09-09 SG SG11201601830PA patent/SG11201601830PA/en unknown
- 2014-09-09 CA CA2923421A patent/CA2923421A1/en not_active Abandoned
- 2014-09-09 CA CA2922901A patent/CA2922901A1/en not_active Abandoned
-
2016
- 2016-02-29 IL IL244343A patent/IL244343A0/en unknown
- 2016-03-06 IL IL244453A patent/IL244453A0/en unknown
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108538365A (zh) * | 2017-03-24 | 2018-09-14 | 华东师范大学 | 一种基于数据分析技术的自闭症社交能力评估系统 |
| CN112055587A (zh) * | 2018-04-13 | 2020-12-08 | Healx有限公司 | 脆性x综合征的治疗 |
| CN112770739A (zh) * | 2018-06-07 | 2021-05-07 | 奥维德医疗公司 | (s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸及相关化合物、(1s,3s)-3-氨基-4-(二氟亚甲基)环戊烷-1-甲酸以及氨己烯酸在治疗发育障碍中的用途 |
| CN112770739B (zh) * | 2018-06-07 | 2023-12-12 | 奥维德医疗公司 | (s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸及相关化合物在治疗发育障碍中的用途 |
| CN115812000A (zh) * | 2020-06-29 | 2023-03-17 | Zyne制药公司 | 大麻二酚对脆性x综合征的治疗 |
| US12582664B2 (en) | 2022-10-20 | 2026-03-24 | Harmony Biosciences Management, Inc. | Treatment of fragile x syndrome with cannabidiol |
Also Published As
| Publication number | Publication date |
|---|---|
| IL244453A0 (en) | 2016-04-21 |
| JP2016530536A (ja) | 2016-09-29 |
| SG11201601605YA (en) | 2016-04-28 |
| SG11201601830PA (en) | 2016-04-28 |
| WO2015033224A3 (en) | 2015-07-02 |
| TW201605443A (zh) | 2016-02-16 |
| CA2923421A1 (en) | 2015-03-12 |
| EA201690557A1 (ru) | 2016-07-29 |
| CA2922901A1 (en) | 2015-03-12 |
| CN105917225A (zh) | 2016-08-31 |
| MX2016003006A (es) | 2016-06-10 |
| WO2015035402A1 (en) | 2015-03-12 |
| MX2016003002A (es) | 2016-09-08 |
| EA201690559A1 (ru) | 2016-08-31 |
| JP2016530291A (ja) | 2016-09-29 |
| WO2015033224A2 (en) | 2015-03-12 |
| IL244343A0 (en) | 2016-04-21 |
| EP3043792A2 (en) | 2016-07-20 |
| TW201606304A (zh) | 2016-02-16 |
| AU2014316779A1 (en) | 2016-03-17 |
| KR20160078956A (ko) | 2016-07-05 |
| KR20160086818A (ko) | 2016-07-20 |
| EP3044589A1 (en) | 2016-07-20 |
| AU2014315026A1 (en) | 2016-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7679304B2 (ja) | 非サイケデリック／精神異常発現性の投与量及び製剤で投与される神経可塑性作用を有する物質を含む組成物並びに使用方法 | |
| CN105517546A (zh) | 治疗脆性x综合征及相关疾病的方法 | |
| US10874644B2 (en) | Therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of synapse function | |
| ES2610508T3 (es) | Métodos para tratar el síndrome de Down, el síndrome del cromosoma X frágil y el autismo | |
| EP1793671B1 (en) | Use of memantine (namenda) to treat autism, compulsivity, and impulsivity | |
| TWI452039B (zh) | 抗神經變性疾病用劑 | |
| US20050065176A1 (en) | Combinations | |
| JP2010504338A (ja) | 筋萎縮性側索硬化症（ＡＬＳ）の治療のための水素化ピリド［４，３−ｂ］インドール | |
| EA024465B1 (ru) | ПРИМЕНЕНИЕ ЛЕВОСИМЕНДАНА ИЛИ ЕГО СОЛЕЙ ДЛЯ ПРИГОТОВЛЕНИЯ МЕДИКАМЕНТА ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА И РОДСТВЕННЫХ РАССТРОЙСТВ ИЛИ ДЛЯ ЗАЩИТЫ ЭНДОТЕЛИАЛЬНЫХ И/ИЛИ НЕРВНЫХ КЛЕТОК ОТ Аβ ТОКСИЧНОСТИ И СПОСОБ ЛЕЧЕНИЯ УКАЗАННЫХ ЗАБОЛЕВАНИЙ | |
| JP2019511495A (ja) | ＧＳＫ３β阻害薬チデグルシブによるＣＤＫＬ５障害の治療 | |
| JP2007517040A (ja) | 睡眠の質を改善するためのメラトニン併用療法 | |
| US10888556B2 (en) | Method for treating myopia with an nsaid and an anti-muscarinic agent | |
| US12144815B2 (en) | Use of aprepitant for treating Alzheimer's disease | |
| JP6137833B2 (ja) | 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用 | |
| US9851354B2 (en) | Methods of treating fragile X syndrome and related disorders | |
| ES2729208T3 (es) | Terapia basada en baclofeno y acamprosato de trastornos de degeneración macular | |
| JP7528065B2 (ja) | Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法および組成物 | |
| CN114072154A (zh) | 用于治疗精神障碍的加波沙朵和锂的组合物 | |
| Sgambellone | Histamine H3 receptor (H3R) antagonist-Nitric Oxide (NO) donor hybrid compounds as a new therapeutic strategy for the treatment of glaucoma and retinal neuroprotection | |
| HK40065529A (en) | Combination of gaboxadol and lithium for the treatment of psychiatric disorders | |
| HK1219691B (zh) | 医药组成物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160420 |
|
| WD01 | Invention patent application deemed withdrawn after publication |